Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.
Olha HalyabarKevin G FriedmanRobert P SundelAnnette L BakerMargaret H ChangPatrick W GouldJane W NewburgerMary Beth F SonPublished in: Pediatric rheumatology online journal (2021)
In KD patients with severe and progressive enlargement of CAA despite anti-inflammatory therapy, CYC seemed to arrest further dilation and was well-tolerated. Future multicenter studies are needed to confirm our findings in this subgroup of KD patients.
Keyphrases
- coronary artery
- end stage renal disease
- anti inflammatory
- newly diagnosed
- ejection fraction
- multiple sclerosis
- low dose
- pulmonary artery
- peritoneal dialysis
- prognostic factors
- early onset
- high dose
- cell cycle
- randomized controlled trial
- cross sectional
- mesenchymal stem cells
- current status
- bone marrow
- combination therapy
- phase iii